Activity report 2022 of the Global Committee

EBMT has made a considerable effort to help our Chinese colleagues to join and not surprisingly this report will deal very much with our common progress in China. 

But the role of the EGC is of course global and we heartily welcome all new members and encourage all members of the EGC to help as much as they can to further increase our scientific knowledge and get benefit for both transplant teams and patients.

The present report is very much oriented to China and the year 2022 has been complicated by COVID. Nonetheless meetings online have never stopped. We hope the next EGC meeting will cover new collaborations with many other countries.

In 2022, three meetings were co-organized by EBMT and Chinese national organisations: two for physicians and one for nurses. Once again the help of the Boxiao foundation including Eva Yu must be acknowledged.

A first EBMT-China inaugural Scientific Forum co-organised by EBMT and the national research centre for translational medicine in Ruijin Hospital, took place  in Shanghai on June 24, 2022, under the co-presidency of our colleagues: Saijuan Chen, Xiaojun Huang, Depei Wu, and He Huang. Weili Zhao and Aibin Liang acted as Executive Presidents. The director of the national centre and a representative of the science and technology commission of the Shanghai municipality assisted us. 300 colleagues were connected online.

A second EBMT-China Scientific Forum co-organized by EBMT, the Institute of haematology and Blood diseases of Tianjin, the Chinese academy of medical sciences and the Pekin Union College, took place in Tianjin on November 18, 2022, under the co-presidency of Jianxiang Wang, Director of the institute and Erlie Jiang, acting as Executive President. The program was devoted to the treatment of Acute Myeloid Leukemia. 500 participants registered and nearly 20,000 watched the forum online since the Tianjin team made a replay of the forum available. Read the event report HERE.

Nicolaus Kroeger, Anna Sureda and Norbert Claude Gorin chaired these forum. 

On the occasion of the 17th National Haematology Academic Conference of the Chinese Medical Association, the first EBMT- China Nursing Forum (in-person and online) was successfully held on September 24, 2022 at the National Exhibition and Convention Center (Shanghai) with the support from Yan Xia, Chairwomen of the Chinese Haematological Disease Nursing Branch and Michelle Kenyon, the EBMT Nurses Group President. Read the event report HERE.

At the time of writing this report, 6 projects have been initiated by EBMT-China. They are listed below:

1. A Chinese national survey of transplant activity in China (around 12,000 transplants per year): Dr CHEN Jia as Principal Investigator ( PI): completed
2. A  retrospective study of the outcomes post haploidentical transplants  comparing first degree versus non first degree donors (oral presentation EBMT 2023): Dr YE Yishan PI: completed
3. A retrospective comparison of autologous versus haploidentical transplants in adult patients with AML in first remission (CR1) with undetectable Minimal Residual Disease (uMRD): Dr CHEN Jia PI (Poster at EBMT 2023): completed
4. A retrospective comparison of autologous versus haplo-identical transplants in adult patients with ALL Philadelphia positive receiving TKI as maintenance therapy: Dr RU Yuhua: in progress
5. A retrospective comparative study of haplo-, MSD and MUD allo-HCTs for AML patients with KMT2A rearrangement: Dr YE Yishan PI (oral presentation at EBMT 2023): patient recruitment still in progress to increase statistical power.
6. Outcome post HSCTof adult patients with AML carrying a TET2 mutation: Dr LI Lin PI: in progress.

The EGC would like to acknowledge the help for these studies of the Acute Leukaemia Working Party and in particular Myriam Labopin, Jacques Emmanuel Galimard, Irma Khevelidze, Mohamed Houhou and Emmanuelle Polge.

The EGC encourages all Chinese teams to propose study projects in association with any of the existing Working Parties. Projects are discussed at the working party meetings and if approved chaired by the proposing investigator considered as the PI.
The EGC wants to remind all EBMT teams that they do have to report ALL CONSECUTIVE DATA ON TRANSPLANTED PATIENTS TO THE REGISTRY TO REMAIN BONA FIDE EBMT TEAM MEMBERS.

During the 48th EBMT Annual Meeting, the ECG organised a session entitled: “GLOBAL PERSPECTIVE FOR CELLULAR IMMUNE THERAPY” with 5 speakers including 4 from Asia.

Membership overview in the last three years